COMMUNIQUÉS West-GlobeNewswire

-
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
20/03/2024 -
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
20/03/2024 -
Gestion Jacques Grimard Inc. acquiert des unités de Groupe LSL Pharma Inc.
19/03/2024 -
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
19/03/2024 -
Cingulate to Participate in Benzinga All Live Access Event
19/03/2024 -
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
19/03/2024 -
Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from March 25 - 27, 2024
19/03/2024 -
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
19/03/2024 -
Tempest Reports Year End 2023 Financial Results and Provides Business Update
19/03/2024 -
Safety Shot Wins Lawsuit Against Capybara Research and Igor Appelboom – Benzinga Retracts Defamatory Story
19/03/2024 -
Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow
19/03/2024 -
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
19/03/2024 -
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints
19/03/2024 -
Nyxoah Annonce que l'Étude Pivot DREAM U.S. Atteint les Critères d'Évaluation Primaires
19/03/2024 -
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
19/03/2024 -
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
19/03/2024 -
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
19/03/2024 -
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
19/03/2024 -
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
19/03/2024
Pages